Catabasis Pharmaceuticals Inc (NASDAQ:CATB) – Investment analysts at Oppenheimer raised their FY2023 earnings per share estimates for shares of Catabasis Pharmaceuticals in a research report issued to clients and investors on Thursday, August 8th. Oppenheimer analyst H. Singh now forecasts that the biotechnology company will post earnings per share of $19.51 for the year, up from their prior forecast of $19.44.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06).

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Catabasis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 16th. Wedbush reiterated an “outperform” rating and set a $18.00 price objective on shares of Catabasis Pharmaceuticals in a research report on Monday, July 29th. Finally, ValuEngine upgraded Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th.

Shares of NASDAQ:CATB opened at $6.40 on Monday. Catabasis Pharmaceuticals has a one year low of $3.60 and a one year high of $9.76. The firm’s fifty day moving average is $7.21. The firm has a market cap of $72.80 million, a P/E ratio of -1.25 and a beta of 1.73. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.25 and a quick ratio of 12.25.

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. increased its stake in Catabasis Pharmaceuticals by 186.8% in the 2nd quarter. BlackRock Inc. now owns 172,679 shares of the biotechnology company’s stock valued at $1,393,000 after buying an additional 112,465 shares during the last quarter. Northern Trust Corp grew its holdings in Catabasis Pharmaceuticals by 74.7% during the 2nd quarter. Northern Trust Corp now owns 50,193 shares of the biotechnology company’s stock valued at $405,000 after buying an additional 21,458 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Catabasis Pharmaceuticals by 321.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 43,406 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 33,106 shares in the last quarter. Wells Fargo & Company MN purchased a new stake in Catabasis Pharmaceuticals during the 2nd quarter valued at approximately $82,000. Finally, Federated Investors Inc. PA grew its holdings in Catabasis Pharmaceuticals by 109.8% during the 1st quarter. Federated Investors Inc. PA now owns 2,189,400 shares of the biotechnology company’s stock valued at $17,340,000 after buying an additional 1,146,000 shares in the last quarter. 36.47% of the stock is owned by institutional investors and hedge funds.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD).

Featured Article: Depreciation

Earnings History and Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.